Outset Medical, Inc. (NASDAQ:OM) Stock Has Consensus Price Target of $10.00

Key Points

• Analyst sentiment is mixed: Outset Medical has a consensus “Hold” rating from five analysts, with one Sell, one Hold, and three Buy recommendations. The average 12-month price target is $10.00 versus the stock’s $4.08 opening price.
• Operating results remain challenging: The company reported a quarterly loss of $0.80 per share, missing expectations of a $0.72 loss, despite revenue of $31.64 million exceeding estimates. Analysts expect a full-year loss of $3.81 per share.
• Shares remain volatile and financially pressured: Outset Medical has a market capitalization of about $76.7 million, a negative net margin of 63.06%, and a 52-week trading range of $2.84 to $14.87, while several institutional investors recently initiated or increased positions.

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) has been given an average rating of "Hold" by the five analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $10.00.

A number of research firms have recently issued reports on OM. Weiss Ratings lowered Outset Medical from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, August 21st. Wall Street Zen upgraded shares of Outset Medical from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th.

Outset Medical Trading Down 0.5%

Shares of OM opened at $4.08 on Tuesday. The stock has a market cap of $76.70 million, a price-to-earnings ratio of -1.00 and a beta of 1.99. The firm has a 50 day simple moving average of $3.74 and a 200-day simple moving average of $4.17. Outset Medical has a 1-year low of $2.84 and a 1-year high of $14.87. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11.

Outset Medical (NASDAQ:OM - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.08). The firm had revenue of $31.64 million for the quarter, compared to analysts' expectations of $28.97 million. Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%. Equities analysts forecast that Outset Medical will post -3.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Outset Medical

Several hedge funds and other institutional investors have recently modified their holdings of the stock. R Squared Ltd acquired a new position in shares of Outset Medical in the 1st quarter worth approximately $65,000. Squarepoint Ops LLC bought a new position in shares of Outset Medical in the 2nd quarter worth about $98,000. Bank of New York Mellon Corp acquired a new position in shares of Outset Medical in the 2nd quarter valued at about $121,000. Sei Investments Co. boosted its holdings in shares of Outset Medical by 15.5% in the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company's stock valued at $136,000 after buying an additional 4,738 shares during the period. Finally, Marquette Asset Management LLC bought a new stake in shares of Outset Medical during the 2nd quarter valued at about $212,000.

Outset Medical Company Profile

Outset Medical, Inc is a medical technology company that develops products for hemodialysis, a treatment that filters waste and excess fluid from the blood when the kidneys are no longer able to do so adequately. The company's primary product is the Tablo Hemodialysis System, an integrated dialysis platform designed to simplify treatment for healthcare providers and support broader use of dialysis in hospitals, outpatient facilities and the home.

The Tablo system combines dialysis delivery, water purification and dialysate production in a single device and uses a touchscreen interface intended to guide users through treatment setup and operation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.